Summary: Retatrutide can cause a dose-dependent increase in resting heart rate, with Phase 2 trials reporting mean rises of approximately 5 to 7 beats per minute at higher doses, likely driven by its GLP-1 and glucagon receptor agonism
Rather than mimicking GHRH, it binds to the growth hormone secretagogue receptor (GHSR-1a) the same receptor your body's own hunger hormone, ghrelin, acts on
Some women find that addressing sleep quality through peptides like ipamorelin , which promotes deeper sleep as a secondary benefit, actually accelerates their fat loss results more than adding another fat-burning compound would
GLP-1 receptor agonists like Foundayo mimic this hormone at a sustained therapeutic level, reducing appetite, limiting calorie intake, and supporting long-term weight loss when combined with diet and exercise
Effective management of bloating during tirzepatide therapy involves both pharmacological considerations and lifestyle modifications
Combination therapies, like GLP-1 with metformin, enhance these effects, offering better results in weight loss and cycle recovery
